Home LiteratureArticle Details
PMID: 7651415 Published · ppublish English Journal Article

Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta.

Molecular and cellular biology ·Vol. 15 ·No. 9 ·1995-09-00 ·Pages 4971-9

Stein B, Yang MX

Abstract

Bone metabolism is regulated by a balance between bone resorption caused by osteoclasts and bone formation caused by osteoblasts. This balance is disturbed in postmenopausal women as a result of lower serum estrogen levels. Estrogen, which is used in hormone replacement therapy to prevent postmenopausal osteoporosis, downregulates expression of the interleukin 6 (IL-6) gene in osteoblasts and bone marrow stromal cells. IL-6 is directly involved in bone resorption by activating immature osteoclasts. We show here that NF-kappa B and C/EBP beta are important regulators of IL-6 gene expression in human osteoblasts. Importantly, the IL-6 promoter is inhibited by estrogen in the absence of a functional estrogen receptor (ER) binding site. This inhibition is mediated by the transcription factors NF-kappa B and C/EBP beta. Evidence is presented for a direct interaction between these two factors and ER. We characterized the protein sequence requirements for this association in vitro and in vivo. The physical and functional interaction depends in part on the DNA binding domain and region D of ER and on the Rel homology domain of NF-kappa B and the bZIP region of C/EBP beta. The cross-coupling between ER, NF-kappa B, and C/EBP beta also results in reduced activity of promoters with ER binding sites. We further show that the mechanism of IL-6 gene repression by estrogen is clearly different from that of activation of promoters with ER binding sites. Therefore, drugs that separate the transactivation and transrepression functions of ER will be very helpful for treatment of osteoporosis without causing undesirable side effects.

MeSH Terms
Base Sequence Binding Sites/genetics CCAAT-Enhancer-Binding Proteins Cell Line DNA-Binding Proteins/analysis,metabolism Estrogens/metabolism Gene Expression Regulation, Developmental I-kappa B Proteins Interleukin-1/pharmacology Interleukin-6/genetics Models, Biological Molecular Sequence Data NF-KappaB Inhibitor alpha NF-kappa B/metabolism Nuclear Proteins/metabolism Osteoblasts/metabolism Osteoporosis/prevention & control Promoter Regions, Genetic/genetics Protein Binding Receptors, Estrogen/metabolism Structure-Activity Relationship Transcription Factors/metabolism
Chemicals
CCAAT-Enhancer-Binding Proteins DNA-Binding Proteins Estrogens I-kappa B Proteins Interleukin-1 Interleukin-6 NF-kappa B NFKBIA protein, human Nuclear Proteins Receptors, Estrogen Transcription Factors NF-KappaB Inhibitor alpha
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Stein B
Signal Pharmaceuticals, San Diego, California 92121, USA.
Yang M X
References (80)
80 references, click to expand
  1. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.
    Science. 1994 Jun 3;264(5164):1455-8 PMID: 8197458
  2. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells.
    Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5227-31 PMID: 8202473
  3. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1.
    J Biol Chem. 1994 Jul 22;269(29):19021-7 PMID: 8034659
  4. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1.
    EMBO J. 1994 Sep 1;13(17):4087-95 PMID: 8076604
  5. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription.
    Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8517-21 PMID: 8078914
  6. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.
    N Engl J Med. 1994 Oct 20;331(16):1056-61 PMID: 8090165
  7. Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha.
    Nucleic Acids Res. 1994 Sep 11;22(18):3787-92 PMID: 7937093
  8. Interaction of proteins with transcriptionally active estrogen receptors.
    Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10009-13 PMID: 7937828
  9. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors.
    Mol Cell Biol. 1995 Feb;15(2):943-53 PMID: 7823959
  10. Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B.
    Mol Cell Biol. 1995 Mar;15(3):1302-11 PMID: 7862124
  11. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids.
    Mol Endocrinol. 1995 Apr;9(4):401-12 PMID: 7659084
  12. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis.
    Obstet Gynecol. 1979 Mar;53(3):277-81 PMID: 218151
  13. Long-term estrogen replacement therapy prevents bone loss and fractures.
    Ann Intern Med. 1985 Mar;102(3):319-24 PMID: 2982302
  14. Early menopausal changes in bone mass and sex steroids.
    J Clin Endocrinol Metab. 1985 Nov;61(5):905-11 PMID: 3930555
  15. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone.
    Endocrinology. 1986 Feb;118(2):824-8 PMID: 3455914
  16. Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts.
    J Exp Med. 1986 Jul 1;164(1):104-12 PMID: 3487611
  17. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro.
    Endocrinology. 1991 Sep;129(3):1513-20 PMID: 1714833
  18. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.
    Blood. 1991 Sep 1;78(5):1198-204 PMID: 1715218
  19. Estrogen binding and estrogenic responses in normal human osteoblast-like cells.
    J Bone Miner Res. 1991 Jun;6(6):531-41 PMID: 1887816
  20. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA.
    Cell. 1991 Nov 1;67(3):569-79 PMID: 1934061
  21. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.
    J Clin Invest. 1992 Jan;89(1):46-52 PMID: 1729280
  22. Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element.
    Mol Endocrinol. 1991 Nov;5(11):1597-606 PMID: 1779966
  23. Parathyroid hormone and lipopolysaccharide induce murine osteoblast-like cells to secrete a cytokine indistinguishable from granulocyte-macrophage colony-stimulating factor.
    J Clin Invest. 1989 Jan;83(1):149-57 PMID: 2642917
  24. Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice.
    Endocrinology. 1989 Mar;124(3):1424-7 PMID: 2917519
  25. Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive element.
    Nature. 1989 Mar 16;338(6212):271-4 PMID: 2922054
  26. Effects of interleukin-1 on bone turnover in normal mice.
    Endocrinology. 1989 Sep;125(3):1142-50 PMID: 2788075
  27. The human estrogen receptor has two independent nonacidic transcriptional activation functions.
    Cell. 1989 Nov 3;59(3):477-87 PMID: 2805068
  28. Interleukin-6 is produced by bone and modulated by parathyroid hormone.
    J Bone Miner Res. 1989 Aug;4(4):633-8 PMID: 2816508
  29. Cooperative binding of estrogen receptor to imperfect estrogen-responsive DNA elements correlates with their synergistic hormone-dependent enhancer activity.
    EMBO J. 1989 Dec 1;8(12):3781-91 PMID: 2583118
  30. Functional and molecular changes in colony stimulating factor secretion by osteoblasts.
    Connect Tissue Res. 1989;20(1-4):159-68 PMID: 2558840
  31. Production of tumor necrosis factor by human osteoblasts is modulated by other cytokines, but not by osteotropic hormones.
    Endocrinology. 1990 Feb;126(2):1250-5 PMID: 2404745
  32. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.
    J Clin Invest. 1992 Mar;89(3):883-91 PMID: 1541679
  33. Identification of a naturally occurring transforming variant of the p65 subunit of NF-kappa B.
    Science. 1992 Apr 17;256(5055):367-70 PMID: 1566083
  34. Risks and benefits of replacement estrogen.
    Annu Rev Med. 1992;43:239-51 PMID: 1580588
  35. Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo.
    EMBO J. 1992 Jun;11(6):2241-6 PMID: 1318196
  36. Interleukin-6: an osteotropic factor?
    J Bone Miner Res. 1992 May;7(5):475-8 PMID: 1615755
  37. Increased osteoclast development after estrogen loss: mediation by interleukin-6.
    Science. 1992 Jul 3;257(5066):88-91 PMID: 1621100
  38. Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kappa B-like nuclear protein.
    J Neuroimmunol. 1992 Aug;39(3):231-42 PMID: 1644898
  39. Interleukin-6 and its receptor: a paradigm for cytokines.
    Science. 1992 Oct 23;258(5082):593-7 PMID: 1411569
  40. Endocrinological aspects of the menopause.
    Br Med Bull. 1992 Apr;48(2):262-75 PMID: 1450871
  41. HRT and osteoporosis.
    Br Med Bull. 1992 Apr;48(2):309-44 PMID: 1450873
  42. Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor.
    EMBO J. 1986 Sep;5(9):2231-6 PMID: 3780678
  43. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption.
    J Immunol. 1987 Feb 1;138(3):775-9 PMID: 3805716
  44. Functional domains of the human estrogen receptor.
    Cell. 1987 Dec 24;51(6):941-51 PMID: 3690665
  45. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells.
    Science. 1988 Jul 1;241(4861):81-4 PMID: 3164526
  46. Evidence of estrogen receptors in normal human osteoblast-like cells.
    Science. 1988 Jul 1;241(4861):84-6 PMID: 3388021
  47. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer.
    Cell. 1988 Oct 7;55(1):145-56 PMID: 3167974
  48. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor.
    Mol Cell Biol. 1990 May;10(5):2327-34 PMID: 2183031
  49. Interleukin-6: an overview.
    Annu Rev Immunol. 1990;8:253-78 PMID: 2188664
  50. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence.
    Mol Cell Biol. 1990 Jul;10(7):3818-23 PMID: 2192263
  51. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone.
    Cell. 1990 Sep 21;62(6):1189-204 PMID: 2169351
  52. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction.
    Cell. 1990 Sep 21;62(6):1205-15 PMID: 2169352
  53. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor.
    Cell. 1990 Sep 21;62(6):1217-26 PMID: 2169353
  54. IL-6 is produced by osteoblasts and induces bone resorption.
    J Immunol. 1990 Nov 15;145(10):3297-303 PMID: 2121824
  55. Biological and clinical aspects of interleukin 6.
    Immunol Today. 1990 Dec;11(12):443-9 PMID: 2127356
  56. Unregulated expression of c-Jun or c-Fos proteins but not Jun D inhibits oestrogen receptor activity in human breast cancer derived cells.
    EMBO J. 1991 Aug;10(8):2237-45 PMID: 1906001
  57. Characterisation of functional inhibition of the glucocorticoid receptor by Fos/Jun.
    Oncogene. 1991 Jul;6(7):1227-34 PMID: 1650443
  58. Future prospects for hormone replacement therapy.
    Br Med Bull. 1992 Apr;48(2):458-68 PMID: 1450879
  59. That oestrogen replacement for osteoporosis prevention should no longer be a bone of contention.
    Ann Rheum Dis. 1993 Jan;52(1):74-80 PMID: 8427521
  60. A nuclear factor for interleukin-6 expression (NF-IL6) and the glucocorticoid receptor synergistically activate transcription of the rat alpha 1-acid glycoprotein gene via direct protein-protein interaction.
    Mol Cell Biol. 1993 Mar;13(3):1854-62 PMID: 8441418
  61. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha.
    Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2532-6 PMID: 8460169
  62. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation.
    Mol Cell Biol. 1993 Jun;13(6):3301-10 PMID: 8497253
  63. Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-Rel and related NF-kappa B proteins in human monocytic THP-1 cells.
    J Biol Chem. 1993 Jun 5;268(16):11803-10 PMID: 8505309
  64. Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction.
    Mol Cell Biol. 1993 Jul;13(7):3964-74 PMID: 8321203
  65. Interleukin-6 inhibits bone formation in vitro.
    Bone Miner. 1993 Apr;21(1):21-8 PMID: 8324417
  66. Demonstration of estrogen and vitamin D receptors in bone marrow-derived stromal cells: up-regulation of the estrogen receptor by 1,25-dihydroxyvitamin-D3.
    Endocrinology. 1993 Aug;133(2):553-62 PMID: 8393768
  67. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal.
    Endocrinology. 1993 Aug;133(2):822-8 PMID: 8393776
  68. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B.
    Nature. 1993 Sep 9;365(6442):182-5 PMID: 8371761
  69. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function.
    EMBO J. 1993 Oct;12(10):3879-91 PMID: 8404856
  70. Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-kappa B.
    Mol Cell Biol. 1993 Nov;13(11):7191-8 PMID: 8413306
  71. Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B.
    Nucleic Acids Res. 1993 Nov 11;21(22):5059-66 PMID: 8255759
  72. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain.
    Mol Endocrinol. 1993 Oct;7(10):1266-74 PMID: 8264659
  73. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor.
    Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):752-6 PMID: 8290595
  74. Impaired immune and acute-phase responses in interleukin-6-deficient mice.
    Nature. 1994 Mar 24;368(6469):339-42 PMID: 8127368
  75. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.
    EMBO J. 1994 Mar 1;13(5):1189-96 PMID: 8131749
  76. 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism.
    J Clin Invest. 1994 Mar;93(3):944-50 PMID: 8132780
  77. Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B.
    Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2225-9 PMID: 8134378
  78. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.
    Mol Endocrinol. 1994 Jan;8(1):21-30 PMID: 8152428
  79. The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family.
    Mol Cell Biol. 1994 May;14(5):3186-96 PMID: 8164674
  80. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor.
    J Biol Chem. 1994 Apr 29;269(17):12940-6 PMID: 8175711
Article Info
Journal
Molecular and cellular biology
Abbr.
Mol Cell Biol
ISSN
0270-7306
DOI
10.1128/MCB.15.9.4971
Published
1995-09-00
Pages
4971-9
Language
English
Region
United States
NLM ID
8109087
PMCID
PMC230744
Subset
IM
External Links
PubMed source DOI: 10.1128/MCB.15.9.4971 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2